Abstract: Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of a payload, e.g., an immunogen, to the reticuloendothelial system via non-circulating lymphoid cells are provided.

Abstract: Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided.

Abstract: Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided.

Abstract: Disclosed herein are materials and methods related to vaccines. Materials and methods for delivery of immunogens to the reticuloendothelial system via non-circulating lymphoid cells are provided.

Abstract: The present invention relates to a polymeric drug conjugate with one or more biologically active agents conjugated via an enzymatically cleavable linker to either a regular repeating linear unit comprising a water soluble polymer segment and a multifunctional chemical moiety, or a branched polymer comprising two or more water soluble polymer segments each bound to a common multifunctional chemical moiety, as well as to methods of making such conjugates. The present invention is also directed to pharmaceutical compositions comprising such conjugates and to the use of such conjugates to treat pathological conditions.

Abstract: A package including absorbent articles and recloseable packaging. The packaging includes a flexible pocket having a hollow interior for said absorbent articles and an opening extending into the hollow interior for permitting an article to be withdrawn from the hollow interior. The packaging also includes a flap having a proximal end attached to the pocket and a distal end opposite the proximal end. The flap may be moved between an open position to permit an article to be withdrawn through the opening and a closed position to retain the articles in the pocket. The flap has a proximal width at the proximal end and a distal width at the distal end shorter than the proximal width.

Abstract: A package including absorbent articles and recloseable packaging. The packaging includes a flexible pocket having a hollow interior for said absorbent articles, an opening extending into the hollow interior for permitting an article to be withdrawn from the hollow interior, and a flap attached to the pocket for covering the opening. The flap may be moved between an open position to permit an article to be withdrawn through the opening and a closed position to retain the articles in the pocket. The packaging also includes a closure positioned on the pocket and/or the flap for releasably holding the flap in the closed position. The closure has an overall length extending between opposite lateral ends thereof which is less than a corresponding width of the pocket.

Abstract: A package including absorbent articles and recloseable packaging. The packaging includes a flexible pocket having a hollow interior for said absorbent articles and an opening extending into the hollow interior for permitting an article to be withdrawn from the hollow interior. The packaging also includes a flap having a proximal end attached to the pocket and a distal end opposite the proximal end. The flap may be moved between an open position to permit an article to be withdrawn through the opening and a closed position to retain the articles in the pocket. The flap has a proximal width at the proximal end and a distal width at the distal end shorter than the proximal width.

Abstract: The invention relates to methods for attenuating xenograft rejection in humans and old world monkeys, using oligosaccharides containing a Gal.alpha.1-3Gal motif, to neutralize or remove anti-.alpha.Gal antibodies. The invention additionally relates to methods for site directed activation of the complement cascade or host leukocytes using oligosaccharides containing a Gal.alpha.1-3Gal motif to target anti-.alpha.Gal antibodies. The invention further relates to pharmaceutical compositions that may be used in the practice of the invention. Such compositions contain, as the active ingredient, an oligosaccharide containing a Gal.alpha.1-3Gal motif effective in binding anti-.alpha.Gal antibodies in vivo or ex vivo.

Abstract: The present invention is directed to compositions for the treatment of respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenza, Burkholderia (Pseudomonas) cepacia, and a mixture thereof, comprising a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc-, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc-;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.

Abstract: A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I(NeuAc-.alpha.(2-3)-pGal-.beta.(1)-(--X--).sub.m --(--Y--).sub.n -).sub.p -ZwhereinX=a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C;Y=a linking group;Z=a multivalent support;m=0 or 1;n=0 or 1; andp=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula IINeuAc-.alpha.(2-3)-pGal-.beta.(1)-AwhereinA=a group capable of bonding to the p galactose;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C.

Abstract: A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I(NeuAc-.alpha.(2-3)-pGal-.beta.(1)--(--X--).sub.m --(--Y--).sub.n --).sub.p --ZwhereinX=a chemical bond or a group capable of linking the p galactose to either the linking group Y or the multivalent support Z;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C;Y=a linking group;Z=a multivalent support;m=0 or 1;n=0 or 1; andp=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula IINeuAc-.alpha.(214 3)-pGal-.beta.(1)-AwhereinA=a group capable of bonding to the p galactose;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C.

Abstract: The present invention is directed to a method of treating respiratory infections caused by a bacteria selected from the group consisting of S. pneumoniae, H. influenzae, H. parainfluenzae, Burkholderia (Pseudomonas) cepacia and a mixture thereof, by administering a binding inhibiting effective amount of the compound of Formula I, ##STR1## where R.sub.1 is H, (.beta.-1)GalNAc--, SO.sub.3 B (where B is H or a cation) or a sialic acid of Formula II; ##STR2## where R.sub.6, R.sub.7, R.sub.8, and R.sub.10 are each independently H, C.sub.1-6 acyl, lactyl, C.sub.1-6 alkyl, sulfate, phosphate, anhydro, a sialic acid of Formula II, (.alpha.-1)Fuc, (.beta.-1)Glc or (.beta.-1)Gal;R.sub.9 is NH--C.sub.1-6 acyl, glycolylamido, amino or hydroxyl; andA is H or a cation;R.sub.2 is H or (.alpha.-1)Fuc--;R.sub.3 and R.sub.4 are each independently OH or NHAc;R.sub.5 is H, SO.sub.

Abstract: A method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula I(NeuAc-.alpha.(2-3)-Gal-.beta.(1)-(--X--).sub.m -(--Y--).sub.n -).sub.p -ZwhereinX=a chemical bond or a group capable of linking the galactose to either the linking group Y or the multivalent support Z;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C;Y=a linking group;Z=a multivalent support;m=0 or 1;n=0 or 1; andp=an integer of 2-1,000 is described. Also described is a method for treating and/or inhibiting gastric and duodenal ulcers, comprising administering a pharmaceutical composition comprising an oligosaccharide of Formula IINeuAc-.alpha.(2-3)-Gal-.beta.(1)-AwhereinA=a group capable of bonding to the galactose;wherein the C.sub.1 glycosidic oxygen of galactose may be replaced by N, S or C.

Abstract: The present invention is directed to immunoassay reagents including specific antibodies to quinoline carboxylic acids, such as brequinar; novel quinoline carboxylic acid haptens useful as standards in immunoassays or for conjugating to large molecular weight carriers as immunogens or conjugating to detectable fluorescent moieties as tracer compounds. The present invention also relates to immunoassays for detecting quinoline carboxylic acids in clinical samples, and finally to kits containing said reagents.